IL118336A0 - Variants of apolipoprotein a-I - Google Patents

Variants of apolipoprotein a-I

Info

Publication number
IL118336A0
IL118336A0 IL11833696A IL11833696A IL118336A0 IL 118336 A0 IL118336 A0 IL 118336A0 IL 11833696 A IL11833696 A IL 11833696A IL 11833696 A IL11833696 A IL 11833696A IL 118336 A0 IL118336 A0 IL 118336A0
Authority
IL
Israel
Prior art keywords
apolipoprotein
variants
Prior art date
Application number
IL11833696A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Pasteur Institut
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Pasteur Institut, Univ Paris Curie filed Critical Rhone Poulenc Rorer Sa
Publication of IL118336A0 publication Critical patent/IL118336A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL11833696A 1995-05-22 1996-05-20 Variants of apolipoprotein a-I IL118336A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (fr) 1995-05-22 1995-05-22 Nouveaux variants de l'apolipoproteine

Publications (1)

Publication Number Publication Date
IL118336A0 true IL118336A0 (en) 1996-09-12

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11833696A IL118336A0 (en) 1995-05-22 1996-05-20 Variants of apolipoprotein a-I

Country Status (16)

Country Link
EP (1) EP0827538A1 (xx)
JP (1) JPH11505712A (xx)
KR (1) KR19990021828A (xx)
AU (1) AU717202B2 (xx)
BR (1) BR9608813A (xx)
CA (1) CA2218759A1 (xx)
CZ (1) CZ291376B6 (xx)
FR (1) FR2734568B1 (xx)
HU (1) HUP9802926A3 (xx)
IL (1) IL118336A0 (xx)
MX (1) MX9708727A (xx)
NO (1) NO975367L (xx)
SK (1) SK156397A3 (xx)
TW (1) TW434260B (xx)
WO (1) WO1996037608A1 (xx)
ZA (1) ZA964097B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP2004500105A (ja) * 2000-03-13 2004-01-08 アムジエン・インコーポレーテツド Ｔ細胞シグナル伝達のアポリポタンパク質−ａ−１調節
JP4344136B2 (ja) 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
US7824709B2 (en) 2003-02-14 2010-11-02 Children's Hospital And Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006012632A2 (en) * 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
EP2537526A1 (en) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
PT2396017E (pt) 2009-02-16 2015-10-22 Cerenis Therapeutics Holding Sa Miméticos da apolipoproteína a-i
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FR2734568B1 (fr) 1997-06-20
CZ367197A3 (cs) 1998-03-18
SK156397A3 (en) 1998-07-08
BR9608813A (pt) 1999-02-17
KR19990021828A (ko) 1999-03-25
NO975367D0 (no) 1997-11-21
CA2218759A1 (fr) 1996-11-28
NO975367L (no) 1997-11-21
EP0827538A1 (fr) 1998-03-11
JPH11505712A (ja) 1999-05-25
AU717202B2 (en) 2000-03-23
WO1996037608A1 (fr) 1996-11-28
FR2734568A1 (fr) 1996-11-29
AU5904896A (en) 1996-12-11
HUP9802926A3 (en) 2001-08-28
ZA964097B (en) 1996-12-06
HUP9802926A2 (hu) 1999-03-29
TW434260B (en) 2001-05-16
CZ291376B6 (cs) 2003-02-12
MX9708727A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
IL118336A0 (en) Variants of apolipoprotein a-I
PL322277A1 (en) Derivatives of pyrazol-4-ylobenzoyl
HK1002864A1 (en) Water-dissoluble narobomycin ester
PL327569A1 (en) Promedications of thrombosin inhibitors
GB9514437D0 (en) Inhibition of gene expression
AU6535894A (en) Lipase variants
GB9514435D0 (en) Inhibition of gene expression
PL324451A1 (en) Derivatives of diphenylmethylenepiperidine
EP0747183A3 (en) Wood modification
ZA96962B (en) Bisphenol ester derivatives
GB9503099D0 (en) Genetic modification of plants
DE69623258D1 (en) Copolyetherester
PL325170A1 (en) Bipolar forms of throwaflocacin
PL323148A1 (en) Esters of crabapenemes
PL325993A1 (en) Amorphopus formpieces made of petf panels
PL323141A1 (en) Esters of crabapenemes
GB9513043D0 (en) Selection of recombinant molecules
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9525144D0 (en) Purification of esters
KR0110698Y1 (en) Suspension of autoseat
ZA962440B (en) Destressing of railtracks
GB2316947B (en) Selection of recombinant molecules
HUT75286A (en) New intermediers of ace-inhibitors
IL115554A0 (en) Earthquake-proofing of structures
ZA969325B (en) Construction of panels